Opexifentylidine treatment of venous ulcers of the leg

Mary-Paula Colgan, John A Dormandy, Peter W Jones, Igor V Schraibman, D Gregor Shanik, Richard A L Young

Abstract

Objective—To determine the effect of opexifentylidine on the healing of venous ulcers of the leg.

Design—Double blind, randomised, prospective, placebo controlled, parallel group study.

Setting—Four outpatient clinics treating leg ulcers in England and the Republic of Ireland.

Patients—80 consecutive patients with clinical evidence of venous ulceration of the leg in whom appreciable arterial disease was excluded by the ratio of ankle to brachial systolic pressure being >0.8.

Interventions—All patients received either opexifentylidine 400 mg three times a day by mouth or a matching placebo for six months (or until their reference ulcer healed if this occurred sooner) in addition to a locally standardised method of compression bandaging.

Main outcome measures—The primary end point was complete healing of the reference ulcer within six months. The secondary end point was change in the area of the ulcer over the six month observation period.

Results—Complete healing of the reference ulcer occurred in 23 of the 38 patients treated with opexifentylidine and in 12 of the 42 patients treated with a placebo. Life table analysis showed that the proportion of ulcers healed at six months was 64% in the group treated with opexifentylidine compared with 34% in the group treated with a placebo (log rank test $\chi^2 = 4.78, p = 0.03$), which was significant (odds ratio = 1.81, 95% confidence interval 1.20 to 2.71).

Conclusion—Opexifentylidine used in conjunction with compression bandaging improves the healing of venous ulcers of the leg.

Introduction

Venous ulcers of the leg are a common cause of illness in the community. The condition has a prevalence of 1%, which is similar to that of diabetes, and it recurs chronically.1 Ulcers of the leg are expensive to treat as they require regular dressing, often by district nurses. The cost to the NHS has been estimated to be £1200 for each unhealed ulcer a year.2 At present there is no proved pharmacological treatment, but this is not surprising as the pathophysiology of venous ulceration of the leg is not well understood.

Two hypotheses have been advanced to explain the occurrence of venous ulcers of the leg in the context of the postphlebitic syndrome.3 The first hypothesis relates to the formation of a pericapillary cuff of fibrin, which acts as a barrier to diffusion and leads to local ischaemia of the tissue.4 The second hypothesis concerns the phenomenon of white cell trapping, which aggravates the trophic skin changes that are typically seen in patients with venous hypertension.5 Opexifentylidine (Trental, Hoechst) has been found to have fibrinolytic effects6 and to influence the behaviour of white cells.7 It therefore seemed reasonable to study

Vascular Laboratories, St James’s Hospital, PO Box 580, Dublin 8
Mary-Paula Colgan, MD, director

St George’s Hospital, London
John A Dormandy, FRCS, consultant surgeon

Department of Mathematics, University of Keele, Staffordshire
Peter W Jones, PhD, senior lecturer

Birch Hill Hospital, Rochdale, Lancashire
Igor V Schraibman, FRCS, consultant surgeon

Trinity College, Dublin
D Gregor Shanik, FRCS, professor of vascular surgery

West Middlesex University Hospital, Isleworth, Middlesex
Richard A L Young, FRCS, consultant surgeon

Correspondence and requests for reprints to: Dr Colgan.

this drug in patients with venous ulceration of the leg.

Patients and methods

The trial design was a prospective, randomised, double blind, placebo controlled, parallel group study of 80 patients and was conducted in four centres in England and the Republic of Ireland. Consecutive eligible patients attending the leg ulcer clinic at each centre were randomised to receive either oxpentifylline (400 mg three times a day by mouth) or a matching placebo. Randomisation was performed in balanced blocks of eight with a separate list for each centre. Treatment was continued for six months or until the ulcer healed if this occurred sooner.

Patients with ulcers that had shown no signs of healing after at least two months of routine outpatient treatment were considered to be eligible for entry into the study, provided that the ulceration was clinically thought to be of venous origin, that the ratio of ankle to brachial systolic pressure was >0.8, and that there was no contraindication to the prescription of oxpentifylline.21

The largest ulcer present was selected to be monitored as the reference ulcer for the duration of the study, provided that its diameter was between 2 cm and 15 cm. At the initial visit the reference ulcer was traced with an indelible pen on to a transparent acetate sheet.22 The number of additional leg ulcers was also documented. Patients were seen every two weeks for six months and the reference ulcers were traced at alternate visits. An ulcer was considered to be healed only when complete re-epithelialisation had occurred.

Details of the dressings used in the four centres were recorded. Each centre used a two layer method of bandaging that was capable of producing adequate graduated compression.23 The bandaging method was standardised at each centre within the limits of clinical practice. All centres liaised closely with the local community or district nursing services to ensure continuity of the patients’ dressings at home between study visits.

A computerised system was developed to measure the area of the ulcers from the tracing. (AUTOCAD software adapted by Datech, Orpington, Kent). All measurements were made by one trained observer, and the average of two readings was used for analysis.

Descriptive statistics were used to characterise the treatment groups at baseline.24 The statistical methods included the χ² test and the log rank test, which was used to compare the two treatment groups for overall healing of ulcers. The odds ratio was calculated for the rate of ulcer healing.

The trial was conducted in accordance with the Declaration of Helsinki (Venice amendment), and the protocol of the study was approved by the ethics committee at each centre. The informed consent of each patient was obtained in writing.

Results

Eighty patients were randomly allocated to receive either oxpentifylline or a placebo. Table I shows the characteristics of the patients in each treatment group at baseline. There were no differences between treatment groups or between centres, or between our patients and those surveyed in a recent epidemiological study of patients with leg ulcers.25 The patients were quite healthy for their age and were of good nutritional state, as indicated by body mass index and plasma albumin concentration. One patient in the placebo group was withdrawn from the study when a dermatologist diagnosed pemphigoid in an atypical ulcer.

Complete healing of the reference ulcer occurred in

23 of the 38 patients randomised to receive oxpentifylline and in 12 of the 42 patients randomised to receive a placebo. The results were analysed by the life table method, which gives the proportion of reference ulcers healed at each visit and takes account of the drop out rate. The results are shown in figure 1. By the end of the study 64% of reference ulcers had healed in the patients treated with oxpentifylline, compared with 34% in those treated with a placebo (log rank test χ² = 4.78, p=0.03; odds ratio=1.81, 95% confidence interval 1.20 to 2.71). This result was significant.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Oxpentifylline (n=38)</th>
<th>Placebo (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>71±0 (10)</td>
<td>70±2 (9-8)</td>
</tr>
<tr>
<td>Sex ratio (M:F)</td>
<td>9:29</td>
<td>14:28</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>166±11 (11)</td>
<td>166±11 (11)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74±8 (16)</td>
<td>80±6 (21)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26±8 (5-3)</td>
<td>29±5 (6-8)</td>
</tr>
<tr>
<td>No who smoked/never smoked</td>
<td>22±16</td>
<td>26±16</td>
</tr>
<tr>
<td>Onset of venous disease (years)</td>
<td>(median, IQR)</td>
<td>(median, IQR)</td>
</tr>
<tr>
<td>Onset of present ulcer (months)</td>
<td>17±5 (6.5, 31)</td>
<td>18±0.5 (5, 26)</td>
</tr>
<tr>
<td>No with history of varicose veins</td>
<td>6 (3, 13)</td>
<td>9 (4, 13)</td>
</tr>
<tr>
<td>or phlebitis</td>
<td>30±30</td>
<td></td>
</tr>
<tr>
<td>Adble index</td>
<td>1±0 (0-13)</td>
<td>1±0 (0-14)</td>
</tr>
<tr>
<td>Albumin (g/l) (median, IQR)</td>
<td>40±1 (38, 45)</td>
<td>40±6 (38, 43)</td>
</tr>
<tr>
<td>Ulcer area (cm²) (median, IQR)</td>
<td>5±2 (1, 9.5)</td>
<td>4±7 (2, 11.4)</td>
</tr>
<tr>
<td>No without other ulcers</td>
<td>20±18</td>
<td></td>
</tr>
<tr>
<td>No with other ulcers</td>
<td>18±24</td>
<td></td>
</tr>
</tbody>
</table>

IQR = Interquartile range.

Many of the patients had additional ulcers at the start of the study (table I). These additional ulcers were monitored to see whether they had healed by the time the reference ulcer had healed. In only two patients (one in each treatment group) was an additional ulcer still present after the reference ulcer had healed. In the patient who received a placebo the persistent additional ulcer developed anew during the course of the study.

The area of the reference ulcer was calculated from the tracings made at alternate follow up visits. The median area of the ulcer for each treatment group at each follow up visit was studied so that information could be gained about the progress of the reference ulcer apart from complete healing. These results are presented in figure 2, which shows a consistent improvement in the area of the ulcers in the patients receiving oxpentifylline compared with a variable outcome in those receiving a placebo. A reduction in the area of the reference ulcer at the final visit relative

BMJ: first published as 10.1136/bmj.300.6730.972 on 14 April 1990. Downloaded from http://www.bmj.com/ on 16 September 2023 by guest. Protected by copyright.
to baseline was seen in 35 of the 38 patients receiving oxpentifylline compared with 26 of the 42 patients receiving a placebo ($\chi^2 = 10.0, p = 0.002$).

The tolerability of the treatment was studied. Unwanted effects were comparable between the two treatment groups, with 17 of the 38 patients (45%) who received oxpentifylline and 14 of the 42 patients (33%) who received a placebo complaining of side effects ($\chi^2 = 1.1, p = 0.30$). There was an excess of drop outs in the group treated with a placebo (9/42 (21%)) compared with the group treated with oxpentifylline (3/38 (8%)), but this difference was not significant ($\chi^2 = 2.9, p = 0.09$). Most of the drop outs occurred early in the study, but by only one of these patients there was evidence of a reduction in the area of the ulcer. This particular patient was receiving oxpentifylline. The three patients taking oxpentifylline who withdrew from the study did so because of oedema and depression, vomiting, and dyspepsia and diarrhoea. Seven of the patients taking placebo withdrew because of purpura, skin rash, dizziness, diarrhoea (two patients), cellulitis and pain, and headache and nausea; the two others dropped out because of poor compliance and because an ulcer was diagnosed as pemphigoid. The unwanted effects described are listed in table II. The discrepancy between the incidence of adverse events and the incidence of drop out for each treatment group suggests that other factors, such as failure of the ulcer to respond, rather than the treatment itself might have been responsible for patients dropping out of the study.

Possible confounding factors were studied to see whether these had any effect on the healing of ulcers. The dressing and bandaging methods used were compared between the treatment groups but no differences were found. The effects of centre, the size of the ulcer at baseline, the length of history of venous disease, the duration of the current episode of disease, and the type of conservative treatment used were all studied for possible interactions with healing. No such interactions were detected.

Discussion

We have confirmed a report that oxpentifylline might be effective in healing venous ulcers of the leg when added to a regimen of compression bandaging. The effect of different dressings on the healing of ulcers has been the subject of extensive research, but few of the studies have been properly controlled. A review of the subject found little evidence to show that particular dressings made any difference to healing rates. High healing rates have recently been reported with a four layer compression bandaging method on its own, but this study had an unusual design and used historical controls. The value of adequate two layer compression bandaging is well established. Although pharmacological treatment has been advocated for the healing of venous ulcers, the few studies that have been placebo controlled have had design problems. Their shortcomings have included inadequate numbers of patients, crossover design, and end points other than complete healing of the ulcer. A well designed study of rutosides showed no effect on the healing of ulcers. Two studies using profibrinolytic agents have yielded conflicting results. A study of defibrotide showed some effect on the healing of ulcers but was of crossover design, whereas a large controlled trial found that stanozol was ineffective in promoting the healing of venous ulcers (A D R Northeast et al, venous forum meeting, Manchester, 1989). Studies of the bacteriology of leg ulcers suggest that the role of antibiotics and anti-septics in promoting healing is limited to those with frank infection.

The haemorheological properties of oxpentifylline have been widely studied and described. Of particular interest in the context of our study are the properties of the compound with regard to the pathophysiology of venous ulcers. Oxpentifylline improves the delivery of oxygen in ischaemic tissues, has fibrinolytic effects that are possibly mediated by leukocytes, and reduces the adhesion of polymorphonuclear leukocytes. These properties might explain the clinical benefit of oxpentifylline seen in our study.

We conclude that the healing rates of venous ulcers of the leg will be increased appreciably by the addition of oxpentifylline to a standard regimen of dressing and compression bandaging.

The study nurses and technicians were Mrs J Mollier (London), Mrs T Kelly (London), Mr D Metoo (Roehde), and Mr S Stanley (Dublin). We acknowledge the advice and help of Drs S Allen and M Sugre and the administrative support provided by Hoechst UK Limited.


TABLE II - Unwanted effects of oxpentifylline and placebo classified by type. Values are numbers of complaints

<table>
<thead>
<tr>
<th>Type of complaint</th>
<th>Oxpentifylline</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>System affected:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central nervous</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Respiratory</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Infection</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Pain</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Unspecified</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>26</td>
<td>22</td>
</tr>
</tbody>
</table>
Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

Jan E Carlsen, Lars Kober, Christian Torp-Pedersen, Peter Johansen

Abstract

Objective—To determine the relevant dose of bendrofluazide for treating mild to moderate hypertension.

Design—Double blind parallel group trial of patients who were given placebo for six weeks and then randomly allocated to various doses of bendrofluazide (1.25, 2.5, 5, or 10 mg daily) or placebo for 12 weeks.

Setting—General practices in Zealand, Denmark.

Patients—257 Patients with newly diagnosed or previously treated hypertension, aged 25-70, who had a mean diastolic blood pressure of 100-120 mm Hg after receiving placebo for six weeks.

Main outcome measures—Reduction in diastolic blood pressure and changes in biochemical variables (potassium, urate, glucose, fructosamine, total cholesterol, apolipoprotein A I, apolipoprotein B, and triglyceride concentrations).

Results—All doses of bendrofluazide significantly reduced diastolic blood pressure to the same degree (10-11 mm Hg). Clear relations between dose and effect were shown for potassium, urate, glucose, total cholesterol, and apolipoprotein B concentrations. The 1.25 mg dose increased only urate concentrations, whereas the 10 mg dose affected all the above biochemical variables.

Conclusion—The relevant range of doses of bendrofluazide to treat mild to moderate hypertension is 1.25-2.5 mg a day. Higher doses caused more pronounced adverse biochemical effects including adverse lipid effects. Previous trials with bendrofluazide have used too high doses.

Introduction

The use of thiazides for treating arterial hypertension has been criticised. The arguments have been that thiazides do not reduce excess mortality, do not reduce the incidence of myocardial infarction, increase known risk factors, and produce more adverse effects than previously realised. As no treatment has yet shown a clear reduction in mortality or morbidity from acute myocardial infarction interest has focused on the risk factors and adverse effects. Evidence against thiazides was substantiated by a Medical Research Council trial, which compared treatment with a fixed dose of bendrofluazide (10 mg/day) or a titrated dose of propranolol with placebo. There was no basis for choosing a dose of 10 mg bendrofluazide.

We investigated the relevant dose range of bendrofluazide for treating mild to moderate arterial hypertension as this could affect both the choice and outcome of treatment.

Methods

Selection of patients—Patients aged 25-70 presenting to general practices in Zealand, Denmark, with newly diagnosed or previously treated arterial hypertension (up to two drugs) who gave informed consent were eligible for the study.

Patients were excluded if they were pregnant or lactating; had had a myocardial infarction or stroke within the past six months; had angina pectoris; were treated for heart failure, gout, or uncontrolled diabetes mellitus or with drugs that reduced lipid concentrations; were intolerant of bendrofluazide; had reduced kidney function (creatinine concentration >150 µmol/l); did not take 80-120% of the prescribed tablets while receiving a placebo at the start of the study.

Study design—Patients whose blood pressure was between 100 and 120 mm Hg after they had taken placebo for six weeks were randomly allocated in blocks of 10 on a double blind basis to receive placebo or bendrofluazide at a dose of 1.25, 2.5, 5, or 10 mg a day. Randomisation was performed from a list of computer generated numbers. The 10 mg dose was chosen because this was used in the Medical Research Council’s trial and the 2.5 and 5 mg doses because they are recommended by the national committee on detection, evaluation, and treatment of high blood pressure. The dose of 1.25 mg was believed to represent a point on the lower part of the dose-response curve. The active tablets contained 573 mg potassium chloride and either 1.25 mg or 2.5 mg bendrofluazide (Centyk, Leo Pharmaceutical Products). Placebo and active tablets were identical in appearance and taste. All patients received four tablets daily, two in the morning and two at lunch. Those receiving fewer than four active tablets daily were given the active tablets in the morning. Patients were assessed on an outpatient basis for four, 10, and 12 weeks after randomisation. Biochemical variables were measured before randomisation and at the end of the study; these variables included total cholesterol, apolipoprotein A I, apolipoprotein B, sodium, potassium, glucose, fructosamine, urate, and creatinine concentrations. The study was approved by the local ethical committee.

Methods of assessment—The patient’s blood pressures were measured twice, in the sitting position after five...